Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07339722 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4515100 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT07339722 is a Phase 1 study of Healthy that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07339722, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.

Conditions Studied

Interventions

  • DRUG LY4515100 via SAD
  • DRUG LY4515100 via MAD

Study Locations (1)

Texas

  • Fortrea Clinical Research Unit - Dallas

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-01-15
Est. Completion 2026-07
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT07339722

The ClinicalTrials.gov registry entry for NCT07339722 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which LY4515100 via SAD is the first listed.

NCT07339722 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07339722 about?

NCT07339722 is a clinical study titled "A Study of LY4515100 in Healthy Participants". The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will inclu...

What is the current status of trial NCT07339722?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-01-15. Estimated completion is 2026-07.

What conditions does trial NCT07339722 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07339722?

The interventions under investigation include: LY4515100 via SAD (DRUG), LY4515100 via MAD (DRUG).

Who is sponsoring clinical trial NCT07339722?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07339722 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.